{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [], "source": [ "from sentence_transformers import SentenceTransformer, util\n", "import pandas as pd\n", "import re\n", "from OpenAITools.JRCTTools import split_target_English, WordProcessor" ] }, { "cell_type": "code", "execution_count": 2, "metadata": {}, "outputs": [], "source": [ "exclusive_words = [\"triple negative\", \"double positive\"]\n", "\n", " # インスタンス作成\n", "processor = WordProcessor(exclusive_words)" ] }, { "cell_type": "code", "execution_count": 15, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241215Cancer.csv', index_col=0)\n", "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n", "# Target列を分割してTargetWord列を追加\n", "basedf['TargetWord'] = basedf['TargetEnglish'].apply(split_target_English)\n", "# 各行のTargetWord列に処理を適用\n", "# NaN や None の場合の処理を追加\n", "basedf['TargetWord'] = basedf['TargetWord'].apply(lambda x: processor(x) if isinstance(x, list) else x)" ] }, { "cell_type": "code", "execution_count": 5, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/huggingface_hub/file_download.py:1132: FutureWarning: `resume_download` is deprecated and will be removed in version 1.0.0. Downloads always resume when possible. If you want to force a new download, use `force_download=True`.\n", " warnings.warn(\n" ] }, { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "0a239a616af243eeb2a08511e21b3a49", "version_major": 2, "version_minor": 0 }, "text/plain": [ "pytorch_model.bin: 0%| | 0.00/438M [00:00, ?B/s]" ] }, "metadata": {}, "output_type": "display_data" }, { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "705ebb2de82e45ffa2aecdf02ef97810", "version_major": 2, "version_minor": 0 }, "text/plain": [ "tokenizer_config.json: 0%| | 0.00/388 [00:00, ?B/s]" ] }, "metadata": {}, "output_type": "display_data" }, { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "835c0af2167247298a44e3ba542b4e05", "version_major": 2, "version_minor": 0 }, "text/plain": [ "vocab.txt: 0%| | 0.00/226k [00:00, ?B/s]" ] }, "metadata": {}, "output_type": "display_data" }, { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "c35026c9786a4c678d430fa06f2d24fe", "version_major": 2, "version_minor": 0 }, "text/plain": [ "tokenizer.json: 0%| | 0.00/461k [00:00, ?B/s]" ] }, "metadata": {}, "output_type": "display_data" }, { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "5125278abc8a49a1b4d9f966fd09ee15", "version_major": 2, "version_minor": 0 }, "text/plain": [ "special_tokens_map.json: 0%| | 0.00/112 [00:00, ?B/s]" ] }, "metadata": {}, "output_type": "display_data" }, { "data": { "application/vnd.jupyter.widget-view+json": { "model_id": "7143cbff16da475dac2cf4727a4939ce", "version_major": 2, "version_minor": 0 }, "text/plain": [ "1_Pooling/config.json: 0%| | 0.00/190 [00:00, ?B/s]" ] }, "metadata": {}, "output_type": "display_data" } ], "source": [ "# モデルのロード\n", "model = SentenceTransformer('pritamdeka/S-PubMedBert-MS-MARCO')" ] }, { "cell_type": "code", "execution_count": 11, "metadata": {}, "outputs": [], "source": [ "# クエリ\n", "#query = \"Triple negative breast cancer\"\n", "query = \"breast cancer\"\n", "#query = \"glioma\"\n", "threshold = 0.925\n", "# クエリをベクトル化\n", "query_vec = model.encode(query, convert_to_tensor=True)\n" ] }, { "cell_type": "code", "execution_count": 19, "metadata": {}, "outputs": [], "source": [ "target_vecs_list = []\n", "for idx, target_words in enumerate(basedf['TargetWord']):\n", " target_vecs = model.encode(target_words, convert_to_tensor=True).cpu()\n", " target_vecs_list.append(target_vecs)\n", "\n", "# Seriesを作成してから代入(dtype=objectを明示)\n", "basedf['TargetVec'] = pd.Series(target_vecs_list, index=basedf.index, dtype=object)\n" ] }, { "cell_type": "code", "execution_count": 20, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", " | JRCT ID | \n", "NCT No | \n", "JapicCTI No | \n", "Title | \n", "TargetJ | \n", "Target | \n", "TargetEnglish | \n", "研究・治験の目的 | \n", "試験等のフェーズ | \n", "試験の種類 | \n", "... | \n", "Inclusion Criteria | \n", "Exclusion Criteria | \n", "Age Minimum | \n", "Age Maximum | \n", "Gender | \n", "Discontinuation Criteria | \n", "Keyword | \n", "Intervention(s) | \n", "TargetWord | \n", "TargetVec | \n", "
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | \n", "jRCT2031240552 | \n", "NCT06599502 | \n", "NaN | \n", "KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併... | \n", "以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌 | \n", "以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌 | \n", "Non-Small Cell Lung Cancer (NSCLC) Pancreatic ... | \n", "Treatment | \n", "1-2 | \n", "NaN | \n", "... | \n", "1. Participant must be 18 years or more, or th... | \n", "1. Any significant laboratory finding or any s... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "AZD0022 | \n", "[Non-Small Cell Lung Cancer (Nsclc) Pancreatic... | \n", "[[tensor(-0.1260), tensor(-0.7142), tensor(-0.... | \n", "
3 | \n", "jRCT2031240547 | \n", "NaN | \n", "NaN | \n", "FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu... | \n", "切除不能進行・再発の胃または食道胃接合部腺癌 | \n", "切除不能進行・再発の胃または食道胃接合部腺癌 | \n", "Advanced Gastric or Gastroesophageal Junction ... | \n", "フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又... | \n", "2 | \n", "NaN | \n", "... | \n", "1) Histologically documented gastric or GEJ ad... | \n", "1) Prior treatment with taxanes 2) Prior treat... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "- Bemarituzumab (15mg/kg, intravenous, Day1, 1... | \n", "[Advanced Gastric, Gastroesophageal Junction C... | \n", "[[tensor(-0.4843), tensor(-0.6084), tensor(-0.... | \n", "
5 | \n", "jRCT2031240542 | \n", "NaN | \n", "NaN | \n", "自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド... | \n", "多発性骨髄腫 | \n", "多発性骨髄腫 | \n", "Multiple Myeloma | \n", "自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ... | \n", "3 | \n", "NaN | \n", "... | \n", "1. Is at least 18 or the legal age of consent ... | \n", "Participants are excluded from the study if an... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm A: Belantamab Mafodotin is intraveniously ... | \n", "[Multiple Myeloma] | \n", "[[tensor(-0.6175), tensor(-0.4283), tensor(-0.... | \n", "
7 | \n", "jRCT2031240536 | \n", "NCT06003231 | \n", "NaN | \n", "既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita... | \n", "頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 | \n", "頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 | \n", "Head and neck squamous cell carcinoma/Non-smal... | \n", "既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形... | \n", "2 | \n", "NaN | \n", "... | \n", "Cohort 1: Head and neck squamous cell carcinom... | \n", "- Prior treatment with a monomethyl auristatin... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Experimental Arm - Disitamab vedotin 1.5 mg/kg... | \n", "[Head, Neck Squamous Cell Carcinoma/Non-Small ... | \n", "[[tensor(-0.2330), tensor(-0.4411), tensor(-0.... | \n", "
9 | \n", "jRCT2031240530 | \n", "NaN | \n", "NaN | \n", "HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra... | \n", "HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... | \n", "HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... | \n", "Stage II-III HER2-Amplified or HER2-Mutant Non... | \n", "HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... | \n", "2 | \n", "NaN | \n", "... | \n", "1. Signed informed consent form 2. Age >= 18 y... | \n", "1. NSCLC that is clinically T4 by virtue of me... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "The study drug will be administered as an IV i... | \n", "[Stage Ii-Iii Her2-Amplified, Her2-Mutant Non-... | \n", "[[tensor(-0.2839), tensor(-0.7334), tensor(-0.... | \n", "
... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "... | \n", "
729 | \n", "jRCT2031200057 | \n", "NaN | \n", "NaN | \n", "治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... | \n", "1 | \n", "NaN | \n", "... | \n", "<Disease Characteristics> 1)Patients with inop... | \n", "1)Patients correspond to either of the followi... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "Breast cancer | \n", "For the target tumor, the dose settled at each... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
739 | \n", "jRCT2073200004 | \n", "NaN | \n", "NaN | \n", "切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験 | \n", "膵癌 | \n", "膵癌 | \n", "Pancreatic cancer | \n", "切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。 | \n", "1-2 | \n", "NaN | \n", "... | \n", "The patients with pancreatic tumors must meet ... | \n", "1) Patients with the following complications: ... | \n", "20age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "Pancreatic ductal carcinoma, unresectable | \n", "Intratumoral administration of oncolytic virus | \n", "[Pancreatic Cancer] | \n", "[[tensor(-0.0844), tensor(-0.9954), tensor(-0.... | \n", "
760 | \n", "jRCT2033190086 | \n", "NaN | \n", "NaN | \n", "悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス1型の第... | \n", "悪性黒色腫 | \n", "悪性黒色腫 | \n", "malignant melanoma | \n", "第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... | \n", "1-2 | \n", "NaN | \n", "... | \n", "(Phase 1) 1) Histologically confirmed malignan... | \n", "(Phase 1 and 2) 1) Patients who have brain and... | \n", "20age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "malignamt melanoma, advanced stage | \n", "Test drug (T-hIL12) will be administered into ... | \n", "[Malignant Melanoma] | \n", "[[tensor(-0.5701), tensor(-0.7062), tensor(-0.... | \n", "
762 | \n", "jRCT2031190072 | \n", "NaN | \n", "NaN | \n", "切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 | \n", "肝細胞癌 | \n", "肝細胞癌 | \n", "Hepatocellular carcinoma | \n", "切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 | \n", "1 | \n", "NaN | \n", "... | \n", "1) Histologically or cytologically confirmed h... | \n", "1) CNS metastases that are symptomatic or requ... | \n", "20age 0month 0week old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "Cancer peptide vaccine | \n", "Reconstitute two kinds of cancer peptide vacci... | \n", "[Hepatocellular Carcinoma] | \n", "[[tensor(-0.1773), tensor(-0.3860), tensor(-0.... | \n", "
772 | \n", "jRCT2051190009 | \n", "NCT03818893 | \n", "JapicCTI-194618 | \n", "進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ(抗PD-1抗体... | \n", "進行性悪性黒色腫 | \n", "進行性悪性黒色腫 | \n", "advanced melanoma | \n", "抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... | \n", "1-2 | \n", "NaN | \n", "... | \n", "Inclusion criteria Patients meeting all of the... | \n", "Exclusion criteria Patients meeting any of the... | \n", "20age old over | \n", "86age old not | \n", "Both | \n", "NaN | \n", "advanced melanoma | \n", "combination therapy of intracutaneous GEN0101 ... | \n", "[Advanced Melanoma] | \n", "[[tensor(-0.5761), tensor(-0.6570), tensor(-0.... | \n", "
427 rows × 41 columns
\n", "\n", " | JRCT ID | \n", "NCT No | \n", "JapicCTI No | \n", "Title | \n", "TargetJ | \n", "Target | \n", "TargetEnglish | \n", "研究・治験の目的 | \n", "試験等のフェーズ | \n", "試験の種類 | \n", "... | \n", "Inclusion Criteria | \n", "Exclusion Criteria | \n", "Age Minimum | \n", "Age Maximum | \n", "Gender | \n", "Discontinuation Criteria | \n", "Keyword | \n", "Intervention(s) | \n", "TargetWord | \n", "TargetVec | \n", "
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | \n", "jRCT2061240081 | \n", "NCT06393374 | \n", "NaN | \n", "術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... | \n", "トリプルネガティブ乳癌 | \n", "トリプルネガティブ乳癌 | \n", "Triple negative breast cancer | \n", "術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... | \n", "3 | \n", "NaN | \n", "... | \n", "-Has centrally confirmed TNBC, as defined by t... | \n", "-Has a known germline breast cancer gene (BRCA... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Arm 1: MK-2870 4mg/kg intravenous (IV) every ... | \n", "[Triple Negative, Breast Cancer] | \n", "[[tensor(-0.2188), tensor(-0.4577), tensor(-0.... | \n", "
32 | \n", "jRCT2031240476 | \n", "NCT06312176 | \n", "NaN | \n", "ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性(HR+/HER2-)の切除不能な局所進行又... | \n", "HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 | \n", "HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 | \n", "HR+/HER2 unresectable locally advanced or meta... | \n", "HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム... | \n", "3 | \n", "NaN | \n", "... | \n", "-Has unresectable locally advanced or metastat... | \n", "-Has breast cancer amenable to treatment with ... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm A:MK-2870 Participants receive 4 mg/kg of ... | \n", "[Hr+/Her2 Unresectable Locally Advanced, Metas... | \n", "[[tensor(0.0489), tensor(-0.7584), tensor(-0.4... | \n", "
157 | \n", "jRCT2052240059 | \n", "NaN | \n", "NaN | \n", "遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... | \n", "2 | \n", "NaN | \n", "... | \n", "1. Histologically confirmed invasive breast ca... | \n", "1. History of other malignancy within the last... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "Omitting breast surgery after preoperative che... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
170 | \n", "jRCT2031240096 | \n", "NCT06380751 | \n", "NaN | \n", "本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... | \n", "進行乳癌 | \n", "進行乳癌 | \n", "Advanced Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "- Adult females, pre/peri-menopausal and/or po... | \n", "- Participants with history of MDS/AML or with... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Experimental: Arm 1: saruparib (AZD5305) plus ... | \n", "[Advanced Breast Cancer] | \n", "[[tensor(-0.2116), tensor(-0.5020), tensor(-0.... | \n", "
209 | \n", "jRCT2031230750 | \n", "NCT06188559 | \n", "NaN | \n", "治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に,... | \n", "HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 | \n", "HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 | \n", "HER2-positive or HER2-low unresectable or meta... | \n", "治療 | \n", "2 | \n", "NaN | \n", "... | \n", "(1) Male or female, aged >=18 years at the tim... | \n", "(1) Presence of brain or subdural metastases, ... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Generic Name:NA Study Treatment in dose optimi... | \n", "[Her2-Positive, Her2-Low Unresectable, Metasta... | \n", "[[tensor(-0.0889), tensor(-0.8979), tensor(-0.... | \n", "
215 | \n", "jRCT2031230723 | \n", "NCT06112379 | \n", "NaN | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "3 | \n", "NaN | \n", "... | \n", "1. Participant must be >= 18 years at the time... | \n", "1. As judged by the investigator, any evidence... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "- Experimental arm: Dato-DXd plus durvalumab n... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
224 | \n", "jRCT2051230196 | \n", "NCT06105632 | \n", "NaN | \n", "CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳... | \n", "ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌 | \n", "ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌 | \n", "HR-positive, HER2-negative Advanced or Metasta... | \n", "CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に... | \n", "3 | \n", "NaN | \n", "... | \n", "* Histological confirmation of breast cancer w... | \n", "* Any medical or psychiatric condition that ma... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm A (Experimental Arm) PF-07220060 plus Fulv... | \n", "[Hr-Positive, Her2-Negative Advanced, Metastat... | \n", "[[tensor(-0.0832), tensor(-0.7572), tensor(-0.... | \n", "
234 | \n", "jRCT2031230677 | \n", "NCT06206837 | \n", "NaN | \n", "18歳以上のER陽性/HER2陰性の進行または転移乳癌患者を対象として,経口タンパク質分解誘... | \n", "エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 | \n", "エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 | \n", "ER+/HER2- advanced or metastatic breast cancer | \n", "進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと... | \n", "1-2 | \n", "NaN | \n", "... | \n", "Inclusion Criteria: * Histological or cytologi... | \n", "Exclusion Criteria: * visceral crisis at risk ... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Drug: vepdegestrant Daily oral dosages of vepd... | \n", "[Er+/Her2- Advanced, Metastatic Breast Cancer] | \n", "[[tensor(-0.1549), tensor(-0.3944), tensor(-0.... | \n", "
240 | \n", "jRCT2061230102 | \n", "NCT06103864 | \n", "NaN | \n", "Programmed death-ligand(PD-L1)陽性の局所再発手術不能又は転移性... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... | \n", "3 | \n", "NaN | \n", "... | \n", "Histologically or cytologically documented loc... | \n", "As judged by investigator, severe or uncontrol... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
307 | \n", "jRCT2061230074 | \n", "NCT05952557 | \n", "NaN | \n", "根治的局所治療(化学療法の併用または非併用)を受けて疾患の兆候のない、再発リスクが中間~高リ... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "- Women and Men; 18 years or more at the time ... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "NaN | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
342 | \n", "jRCT2051230094 | \n", "NCT05794906 | \n", "NaN | \n", "前立腺癌の高リスク生化学的再発(BCR)患者を対象としたアンドロゲン遮断療法(ADT)を併用... | \n", "前立腺癌 | \n", "前立腺癌 | \n", "prostate cancer | \n", "BAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ... | \n", "3 | \n", "NaN | \n", "... | \n", "- Histologically or cytologically confirmed ad... | \n", "- Pathological finding consistent with small c... | \n", "18age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "Drug: Darolutamide (BAY1841788, Nubeqa) Coated... | \n", "[Prostate Cancer] | \n", "[[tensor(0.0202), tensor(-0.7650), tensor(-0.5... | \n", "
351 | \n", "jRCT2031230279 | \n", "NCT05862285 | \n", "NaN | \n", "GENENTECH社及び/又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... | \n", "癌 | \n", "癌 | \n", "Cancer | \n", "本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... | \n", "3 | \n", "NaN | \n", "... | \n", "- Eligible for continuing Roche IMP-based ther... | \n", "- Meet any of the study treatment discontinuat... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Ipatasertib: Ipatasertib will be administered ... | \n", "[Cancer] | \n", "[[tensor(-0.2145), tensor(-0.7045), tensor(-0.... | \n", "
385 | \n", "jRCT2031230121 | \n", "NCT04557449 | \n", "NaN | \n", "進行固形がん患者を対象として,PF-07220060 の単剤投与および併用投与の安全性,忍容... | \n", "進行または転移性の乳癌,前立腺癌,およびその他の固形癌 | \n", "進行または転移性の乳癌,前立腺癌,およびその他の固形癌 | \n", "advanced or metastatic BC, prostate cancer or ... | \n", "パート1(用量漸増,食事の影響,DDIの評価パート) 1A: PF-07220060のMTD... | \n", "1 | \n", "NaN | \n", "... | \n", "Disease * Part 1A/1D/1E: HR+HER2-BC, HR+HER2+B... | \n", "* Part 1D: participants who have had a gastrec... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "* Part 1A/1D/1E: PF-07220060 (CDK4 inhibitor) ... | \n", "[Advanced, Metastatic Bc, Prostate Cancer, Oth... | \n", "[[tensor(-0.4654), tensor(-0.4115), tensor(-0.... | \n", "
388 | \n", "jRCT2031230109 | \n", "NCT05514054 | \n", "NaN | \n", "EMBER-4:2~5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Neoplasms | \n", "早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 | \n", "3 | \n", "NaN | \n", "... | \n", "-Have a diagnosis of ER+, HER2- early-stage, r... | \n", "-Have any evidence of metastatic disease (incl... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: Imlunestrant Administered orally. Other... | \n", "[Breast Neoplasms] | \n", "[[tensor(-0.3342), tensor(-0.6973), tensor(-0.... | \n", "
391 | \n", "jRCT2031230090 | \n", "NaN | \n", "NaN | \n", "MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ... | \n", "再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん | \n", "再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん | \n", "Relapsed/Refractory Locally Advanced or Metast... | \n", "再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する... | \n", "1 | \n", "NaN | \n", "... | \n", "Dose Escalation and Dose Expansion Cohorts 1. ... | \n", "Dose Escalation and Expansion Cohorts 1. Women... | \n", "18age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "This is a Phase I dose escalation/expansion mu... | \n", "[Relapsed/Refract, Y Locally Advanced, Metasta... | \n", "[[tensor(-0.0153), tensor(-0.4994), tensor(-0.... | \n", "
392 | \n", "jRCT2031230096 | \n", "NCT05774951 | \n", "NaN | \n", "根治的局所領域療法(化学療法の併用または非併用)および標準補助内分泌療法(ET)を少なくとも... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "- Women and Men, greater than or equal to 18 y... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
402 | \n", "jRCT2061230009 | \n", "NCT05485766 | \n", "NaN | \n", "gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP... | \n", "トリプルネガティブ乳がん | \n", "トリプルネガティブ乳がん | \n", "Triple Negative Breast Neoplasms | \n", "術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク... | \n", "2 | \n", "NaN | \n", "... | \n", "1)Male/female subjects who are at least 18 yea... | \n", "1) Subjects who has a positive urine pregnancy... | \n", "18age old exceed | \n", "No limit | \n", "Both | \n", "NaN | \n", "Triple Negative Breast Cancer, Breast Neoplasm... | \n", "Drug: Pembrolizumab 200 mg fixed dose, IV, eve... | \n", "[Triple Negative, Breast Neoplasms] | \n", "[[tensor(-0.2188), tensor(-0.4577), tensor(-0.... | \n", "
463 | \n", "jRCT2061220087 | \n", "NCT05629585 | \n", "NaN | \n", "術前薬物療法後の外科的切除時に乳房及び/又は腋窩リンパ節に浸潤性残存病変を有するステージI~... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... | \n", "3 | \n", "NaN | \n", "... | \n", "Participant must be >= 18 years at the time of... | \n", "Stage IV (metastatic) TNBC. History of prior i... | \n", "18age old over | \n", "130age old under | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
515 | \n", "jRCT2031220276 | \n", "NCT05307705 | \n", "NaN | \n", "PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... | \n", "乳がん | \n", "乳がん | \n", "Breast Cancer | \n", "LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... | \n", "1 | \n", "NaN | \n", "... | \n", "-Have advanced breast cancer or another solid ... | \n", "-Medical Conditions -Colorectal cancer -Endome... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
555 | \n", "jRCT2031220034 | \n", "NCT04862663 | \n", "NaN | \n", "局所進行(切除不能)又は転移性のホルモン受容体陽性/ヒト上皮細胞成長因子受容体2 陰性乳癌を... | \n", "局所進行(切除不能)又は転移性乳癌 | \n", "局所進行(切除不能)又は転移性乳癌 | \n", "Locally Advanced (Inoperable) or Metastatic Br... | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "Key inclusion criteria for both phases: 1. Adu... | \n", "Key exclusion criteria for both phases: 1. His... | \n", "18age old over | \n", "99age old under | \n", "Both | \n", "NaN | \n", "NaN | \n", "Capivasertib: PO BD 4 days on /3 days off per ... | \n", "[Locally Advanced (Inoperable), Metastatic Bre... | \n", "[[tensor(-0.1555), tensor(-0.8327), tensor(-0.... | \n", "
590 | \n", "jRCT2031210585 | \n", "NCT05123482 | \n", "NaN | \n", "進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... | \n", "乳癌、胆道癌、卵巣癌、子宮内膜癌 | \n", "乳癌、胆道癌、卵巣癌、子宮内膜癌 | \n", "Breast Cancer, Biliary Tract Carcinoma, Ovaria... | \n", "進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 | \n", "1-2 | \n", "NaN | \n", "... | \n", "- Age18 years or more - Relapsed/metastatic so... | \n", "- Treatment with any of the following: 1. Nitr... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Sub-study1 AZD8205 Monotherapy AZD8205 is an a... | \n", "[Breast Cancer, Biliary Tract Carcinoma, Ovari... | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
593 | \n", "jRCT2031210560 | \n", "NCT05061823 | \n", "NaN | \n", "複数のBintrafusp alfa(M7824)臨床試験の被験者を対象に長期データを収集す... | \n", "固形癌 | \n", "固形癌 | \n", "Cancer | \n", "本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... | \n", "3 | \n", "NaN | \n", "... | \n", "- Participants who are currently enrolled in a... | \n", "- Participants who are pregnant or currently i... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Participants who are continuing treatment with... | \n", "[Cancer] | \n", "[[tensor(-0.2145), tensor(-0.7045), tensor(-0.... | \n", "
600 | \n", "jRCT2041210123 | \n", "NCT05114746 | \n", "NaN | \n", "進行性PSMA陽性転移性去勢抵抗性前立腺がん(mCRPC)を有する患者を対象に177Lu-P... | \n", "前立腺癌 | \n", "前立腺癌 | \n", "Prostate Cancer | \n", "本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与... | \n", "2 | \n", "NaN | \n", "... | \n", "- ECOG performance status: 1. Post-taxane popu... | \n", "- Previous treatment with any of the following... | \n", "20age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "Radiation: 177Lu-PSMA-617 administered intrave... | \n", "[Prostate Cancer] | \n", "[[tensor(0.0202), tensor(-0.7650), tensor(-0.5... | \n", "
629 | \n", "jRCT2052210099 | \n", "NaN | \n", "NaN | \n", "乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... | \n", "2 | \n", "NaN | \n", "... | \n", "Breast cancer (including suspected) (1) One of... | \n", "(1) There is trauma with bleeding on the breas... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "The test using IGS-0001 will be performed twic... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
691 | \n", "jRCT2031200384 | \n", "NCT04221542 | \n", "NaN | \n", "転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性... | \n", "前立腺がん | \n", "前立腺がん | \n", "Prostate Cancer | \n", "成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用... | \n", "1 | \n", "NaN | \n", "... | \n", "- Parts 1, 2, and 5: Participants with histolo... | \n", "- Pathological finding consistent with pure sm... | \n", "18age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "- Experimental: Part 1: AMG 509 Intravenous (I... | \n", "[Prostate Cancer] | \n", "[[tensor(0.0202), tensor(-0.7650), tensor(-0.5... | \n", "
698 | \n", "jRCT2071200086 | \n", "NCT04640623 | \n", "NaN | \n", "膀胱全摘除術に不適格である,又は膀胱全摘除術を選択しなかった,カルメット・ゲラン桿菌(BCG... | \n", "膀胱癌 | \n", "膀胱癌 | \n", "Bladder Cancer | \n", "試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT... | \n", "2 | \n", "NaN | \n", "... | \n", "- Histologically confirmed diagnosis of persis... | \n", "- Histologically confirmed, muscle-invasive, l... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-... | \n", "[Bladder Cancer] | \n", "[[tensor(-0.2062), tensor(-0.5714), tensor(-0.... | \n", "
729 | \n", "jRCT2031200057 | \n", "NaN | \n", "NaN | \n", "治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... | \n", "1 | \n", "NaN | \n", "... | \n", "<Disease Characteristics> 1)Patients with inop... | \n", "1)Patients correspond to either of the followi... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "Breast cancer | \n", "For the target tumor, the dose settled at each... | \n", "[Breast Cancer] | \n", "[[tensor(-0.0986), tensor(-0.6295), tensor(-0.... | \n", "
27 rows × 41 columns
\n", "\n", " | JRCT ID | \n", "NCT No | \n", "JapicCTI No | \n", "Title | \n", "TargetJ | \n", "Target | \n", "TargetEnglish | \n", "研究・治験の目的 | \n", "試験等のフェーズ | \n", "試験の種類 | \n", "... | \n", "purpose | \n", "Inclusion Criteria | \n", "Exclusion Criteria | \n", "Age Minimum | \n", "Age Maximum | \n", "Gender | \n", "Discontinuation Criteria | \n", "Keyword | \n", "Intervention(s) | \n", "TargetWord | \n", "
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | \n", "jRCT2061240081 | \n", "NCT06393374 | \n", "NaN | \n", "術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... | \n", "トリプルネガティブ乳癌 | \n", "トリプルネガティブ乳癌 | \n", "Triple negative breast cancer | \n", "術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Has centrally confirmed TNBC, as defined by t... | \n", "-Has a known germline breast cancer gene (BRCA... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Arm 1: MK-2870 4mg/kg intravenous (IV) every ... | \n", "[Triple Negative, Breast Cancer] | \n", "
32 | \n", "jRCT2031240476 | \n", "NCT06312176 | \n", "NaN | \n", "ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性(HR+/HER2-)の切除不能な局所進行又... | \n", "HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 | \n", "HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 | \n", "HR+/HER2 unresectable locally advanced or meta... | \n", "HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Has unresectable locally advanced or metastat... | \n", "-Has breast cancer amenable to treatment with ... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm A:MK-2870 Participants receive 4 mg/kg of ... | \n", "[Hr+/Her2 Unresectable Locally Advanced, Metas... | \n", "
157 | \n", "jRCT2052240059 | \n", "NaN | \n", "NaN | \n", "遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... | \n", "2 | \n", "NaN | \n", "... | \n", "diagnostic purpose | \n", "1. Histologically confirmed invasive breast ca... | \n", "1. History of other malignancy within the last... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "Omitting breast surgery after preoperative che... | \n", "[Breast Cancer] | \n", "
170 | \n", "jRCT2031240096 | \n", "NCT06380751 | \n", "NaN | \n", "本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... | \n", "進行乳癌 | \n", "進行乳癌 | \n", "Advanced Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Adult females, pre/peri-menopausal and/or po... | \n", "- Participants with history of MDS/AML or with... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Experimental: Arm 1: saruparib (AZD5305) plus ... | \n", "[Advanced Breast Cancer] | \n", "
209 | \n", "jRCT2031230750 | \n", "NCT06188559 | \n", "NaN | \n", "治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に,... | \n", "HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 | \n", "HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 | \n", "HER2-positive or HER2-low unresectable or meta... | \n", "治療 | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "(1) Male or female, aged >=18 years at the tim... | \n", "(1) Presence of brain or subdural metastases, ... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Generic Name:NA Study Treatment in dose optimi... | \n", "[Her2-Positive, Her2-Low Unresectable, Metasta... | \n", "
215 | \n", "jRCT2031230723 | \n", "NCT06112379 | \n", "NaN | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "1. Participant must be >= 18 years at the time... | \n", "1. As judged by the investigator, any evidence... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "- Experimental arm: Dato-DXd plus durvalumab n... | \n", "[Breast Cancer] | \n", "
224 | \n", "jRCT2051230196 | \n", "NCT06105632 | \n", "NaN | \n", "CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳... | \n", "ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌 | \n", "ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌 | \n", "HR-positive, HER2-negative Advanced or Metasta... | \n", "CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "* Histological confirmation of breast cancer w... | \n", "* Any medical or psychiatric condition that ma... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm A (Experimental Arm) PF-07220060 plus Fulv... | \n", "[Hr-Positive, Her2-Negative Advanced, Metastat... | \n", "
234 | \n", "jRCT2031230677 | \n", "NCT06206837 | \n", "NaN | \n", "18歳以上のER陽性/HER2陰性の進行または転移乳癌患者を対象として,経口タンパク質分解誘... | \n", "エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 | \n", "エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 | \n", "ER+/HER2- advanced or metastatic breast cancer | \n", "進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと... | \n", "1-2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Inclusion Criteria: * Histological or cytologi... | \n", "Exclusion Criteria: * visceral crisis at risk ... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Drug: vepdegestrant Daily oral dosages of vepd... | \n", "[Er+/Her2- Advanced, Metastatic Breast Cancer] | \n", "
240 | \n", "jRCT2061230102 | \n", "NCT06103864 | \n", "NaN | \n", "Programmed death-ligand(PD-L1)陽性の局所再発手術不能又は転移性... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Histologically or cytologically documented loc... | \n", "As judged by investigator, severe or uncontrol... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... | \n", "[Breast Cancer] | \n", "
307 | \n", "jRCT2061230074 | \n", "NCT05952557 | \n", "NaN | \n", "根治的局所治療(化学療法の併用または非併用)を受けて疾患の兆候のない、再発リスクが中間~高リ... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Women and Men; 18 years or more at the time ... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "NaN | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "
342 | \n", "jRCT2051230094 | \n", "NCT05794906 | \n", "NaN | \n", "前立腺癌の高リスク生化学的再発(BCR)患者を対象としたアンドロゲン遮断療法(ADT)を併用... | \n", "前立腺癌 | \n", "前立腺癌 | \n", "prostate cancer | \n", "BAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Histologically or cytologically confirmed ad... | \n", "- Pathological finding consistent with small c... | \n", "18age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "Drug: Darolutamide (BAY1841788, Nubeqa) Coated... | \n", "[Prostate Cancer] | \n", "
351 | \n", "jRCT2031230279 | \n", "NCT05862285 | \n", "NaN | \n", "GENENTECH社及び/又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... | \n", "癌 | \n", "癌 | \n", "Cancer | \n", "本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Eligible for continuing Roche IMP-based ther... | \n", "- Meet any of the study treatment discontinuat... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Ipatasertib: Ipatasertib will be administered ... | \n", "[Cancer] | \n", "
385 | \n", "jRCT2031230121 | \n", "NCT04557449 | \n", "NaN | \n", "進行固形がん患者を対象として,PF-07220060 の単剤投与および併用投与の安全性,忍容... | \n", "進行または転移性の乳癌,前立腺癌,およびその他の固形癌 | \n", "進行または転移性の乳癌,前立腺癌,およびその他の固形癌 | \n", "advanced or metastatic BC, prostate cancer or ... | \n", "パート1(用量漸増,食事の影響,DDIの評価パート) 1A: PF-07220060のMTD... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Disease * Part 1A/1D/1E: HR+HER2-BC, HR+HER2+B... | \n", "* Part 1D: participants who have had a gastrec... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "* Part 1A/1D/1E: PF-07220060 (CDK4 inhibitor) ... | \n", "[Advanced, Metastatic Bc, Prostate Cancer, Oth... | \n", "
388 | \n", "jRCT2031230109 | \n", "NCT05514054 | \n", "NaN | \n", "EMBER-4:2~5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Neoplasms | \n", "早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Have a diagnosis of ER+, HER2- early-stage, r... | \n", "-Have any evidence of metastatic disease (incl... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: Imlunestrant Administered orally. Other... | \n", "[Breast Neoplasms] | \n", "
391 | \n", "jRCT2031230090 | \n", "NaN | \n", "NaN | \n", "MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ... | \n", "再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん | \n", "再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん | \n", "Relapsed/Refractory Locally Advanced or Metast... | \n", "再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Dose Escalation and Dose Expansion Cohorts 1. ... | \n", "Dose Escalation and Expansion Cohorts 1. Women... | \n", "18age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "This is a Phase I dose escalation/expansion mu... | \n", "[Relapsed/Refract, Y Locally Advanced, Metasta... | \n", "
392 | \n", "jRCT2031230096 | \n", "NCT05774951 | \n", "NaN | \n", "根治的局所領域療法(化学療法の併用または非併用)および標準補助内分泌療法(ET)を少なくとも... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Women and Men, greater than or equal to 18 y... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "
402 | \n", "jRCT2061230009 | \n", "NCT05485766 | \n", "NaN | \n", "gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP... | \n", "トリプルネガティブ乳がん | \n", "トリプルネガティブ乳がん | \n", "Triple Negative Breast Neoplasms | \n", "術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク... | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "1)Male/female subjects who are at least 18 yea... | \n", "1) Subjects who has a positive urine pregnancy... | \n", "18age old exceed | \n", "No limit | \n", "Both | \n", "NaN | \n", "Triple Negative Breast Cancer, Breast Neoplasm... | \n", "Drug: Pembrolizumab 200 mg fixed dose, IV, eve... | \n", "[Triple Negative, Breast Neoplasms] | \n", "
463 | \n", "jRCT2061220087 | \n", "NCT05629585 | \n", "NaN | \n", "術前薬物療法後の外科的切除時に乳房及び/又は腋窩リンパ節に浸潤性残存病変を有するステージI~... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Participant must be >= 18 years at the time of... | \n", "Stage IV (metastatic) TNBC. History of prior i... | \n", "18age old over | \n", "130age old under | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... | \n", "[Breast Cancer] | \n", "
515 | \n", "jRCT2031220276 | \n", "NCT05307705 | \n", "NaN | \n", "PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... | \n", "乳がん | \n", "乳がん | \n", "Breast Cancer | \n", "LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Have advanced breast cancer or another solid ... | \n", "-Medical Conditions -Colorectal cancer -Endome... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... | \n", "[Breast Cancer] | \n", "
555 | \n", "jRCT2031220034 | \n", "NCT04862663 | \n", "NaN | \n", "局所進行(切除不能)又は転移性のホルモン受容体陽性/ヒト上皮細胞成長因子受容体2 陰性乳癌を... | \n", "局所進行(切除不能)又は転移性乳癌 | \n", "局所進行(切除不能)又は転移性乳癌 | \n", "Locally Advanced (Inoperable) or Metastatic Br... | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Key inclusion criteria for both phases: 1. Adu... | \n", "Key exclusion criteria for both phases: 1. His... | \n", "18age old over | \n", "99age old under | \n", "Both | \n", "NaN | \n", "NaN | \n", "Capivasertib: PO BD 4 days on /3 days off per ... | \n", "[Locally Advanced (Inoperable), Metastatic Bre... | \n", "
590 | \n", "jRCT2031210585 | \n", "NCT05123482 | \n", "NaN | \n", "進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... | \n", "乳癌、胆道癌、卵巣癌、子宮内膜癌 | \n", "乳癌、胆道癌、卵巣癌、子宮内膜癌 | \n", "Breast Cancer, Biliary Tract Carcinoma, Ovaria... | \n", "進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 | \n", "1-2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Age18 years or more - Relapsed/metastatic so... | \n", "- Treatment with any of the following: 1. Nitr... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Sub-study1 AZD8205 Monotherapy AZD8205 is an a... | \n", "[Breast Cancer, Biliary Tract Carcinoma, Ovari... | \n", "
593 | \n", "jRCT2031210560 | \n", "NCT05061823 | \n", "NaN | \n", "複数のBintrafusp alfa(M7824)臨床試験の被験者を対象に長期データを収集す... | \n", "固形癌 | \n", "固形癌 | \n", "Cancer | \n", "本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Participants who are currently enrolled in a... | \n", "- Participants who are pregnant or currently i... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Participants who are continuing treatment with... | \n", "[Cancer] | \n", "
600 | \n", "jRCT2041210123 | \n", "NCT05114746 | \n", "NaN | \n", "進行性PSMA陽性転移性去勢抵抗性前立腺がん(mCRPC)を有する患者を対象に177Lu-P... | \n", "前立腺癌 | \n", "前立腺癌 | \n", "Prostate Cancer | \n", "本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与... | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- ECOG performance status: 1. Post-taxane popu... | \n", "- Previous treatment with any of the following... | \n", "20age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "Radiation: 177Lu-PSMA-617 administered intrave... | \n", "[Prostate Cancer] | \n", "
629 | \n", "jRCT2052210099 | \n", "NaN | \n", "NaN | \n", "乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... | \n", "2 | \n", "NaN | \n", "... | \n", "screening | \n", "Breast cancer (including suspected) (1) One of... | \n", "(1) There is trauma with bleeding on the breas... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "The test using IGS-0001 will be performed twic... | \n", "[Breast Cancer] | \n", "
691 | \n", "jRCT2031200384 | \n", "NCT04221542 | \n", "NaN | \n", "転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性... | \n", "前立腺がん | \n", "前立腺がん | \n", "Prostate Cancer | \n", "成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Parts 1, 2, and 5: Participants with histolo... | \n", "- Pathological finding consistent with pure sm... | \n", "18age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "- Experimental: Part 1: AMG 509 Intravenous (I... | \n", "[Prostate Cancer] | \n", "
698 | \n", "jRCT2071200086 | \n", "NCT04640623 | \n", "NaN | \n", "膀胱全摘除術に不適格である,又は膀胱全摘除術を選択しなかった,カルメット・ゲラン桿菌(BCG... | \n", "膀胱癌 | \n", "膀胱癌 | \n", "Bladder Cancer | \n", "試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT... | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Histologically confirmed diagnosis of persis... | \n", "- Histologically confirmed, muscle-invasive, l... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-... | \n", "[Bladder Cancer] | \n", "
729 | \n", "jRCT2031200057 | \n", "NaN | \n", "NaN | \n", "治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "<Disease Characteristics> 1)Patients with inop... | \n", "1)Patients correspond to either of the followi... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "Breast cancer | \n", "For the target tumor, the dose settled at each... | \n", "[Breast Cancer] | \n", "
27 rows × 40 columns
\n", "\n", " | JRCT ID | \n", "NCT No | \n", "JapicCTI No | \n", "Title | \n", "TargetJ | \n", "Target | \n", "TargetEnglish | \n", "研究・治験の目的 | \n", "試験等のフェーズ | \n", "試験の種類 | \n", "... | \n", "purpose | \n", "Inclusion Criteria | \n", "Exclusion Criteria | \n", "Age Minimum | \n", "Age Maximum | \n", "Gender | \n", "Discontinuation Criteria | \n", "Keyword | \n", "Intervention(s) | \n", "TargetWord | \n", "
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
31 | \n", "jRCT2061240081 | \n", "NCT06393374 | \n", "NaN | \n", "術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... | \n", "トリプルネガティブ乳癌 | \n", "トリプルネガティブ乳癌 | \n", "Triple negative breast cancer | \n", "術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Has centrally confirmed TNBC, as defined by t... | \n", "-Has a known germline breast cancer gene (BRCA... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Arm 1: MK-2870 4mg/kg intravenous (IV) every ... | \n", "[Triple Negative, Breast Cancer] | \n", "
157 | \n", "jRCT2052240059 | \n", "NaN | \n", "NaN | \n", "遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... | \n", "2 | \n", "NaN | \n", "... | \n", "diagnostic purpose | \n", "1. Histologically confirmed invasive breast ca... | \n", "1. History of other malignancy within the last... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "Omitting breast surgery after preoperative che... | \n", "[Breast Cancer] | \n", "
215 | \n", "jRCT2031230723 | \n", "NCT06112379 | \n", "NaN | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "1. Participant must be >= 18 years at the time... | \n", "1. As judged by the investigator, any evidence... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "- Experimental arm: Dato-DXd plus durvalumab n... | \n", "[Breast Cancer] | \n", "
240 | \n", "jRCT2061230102 | \n", "NCT06103864 | \n", "NaN | \n", "Programmed death-ligand(PD-L1)陽性の局所再発手術不能又は転移性... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Histologically or cytologically documented loc... | \n", "As judged by investigator, severe or uncontrol... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... | \n", "[Breast Cancer] | \n", "
307 | \n", "jRCT2061230074 | \n", "NCT05952557 | \n", "NaN | \n", "根治的局所治療(化学療法の併用または非併用)を受けて疾患の兆候のない、再発リスクが中間~高リ... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Women and Men; 18 years or more at the time ... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "NaN | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "
388 | \n", "jRCT2031230109 | \n", "NCT05514054 | \n", "NaN | \n", "EMBER-4:2~5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Neoplasms | \n", "早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Have a diagnosis of ER+, HER2- early-stage, r... | \n", "-Have any evidence of metastatic disease (incl... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: Imlunestrant Administered orally. Other... | \n", "[Breast Neoplasms] | \n", "
391 | \n", "jRCT2031230090 | \n", "NaN | \n", "NaN | \n", "MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ... | \n", "再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん | \n", "再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん | \n", "Relapsed/Refractory Locally Advanced or Metast... | \n", "再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Dose Escalation and Dose Expansion Cohorts 1. ... | \n", "Dose Escalation and Expansion Cohorts 1. Women... | \n", "18age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "This is a Phase I dose escalation/expansion mu... | \n", "[Relapsed/Refract, Y Locally Advanced, Metasta... | \n", "
392 | \n", "jRCT2031230096 | \n", "NCT05774951 | \n", "NaN | \n", "根治的局所領域療法(化学療法の併用または非併用)および標準補助内分泌療法(ET)を少なくとも... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Women and Men, greater than or equal to 18 y... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "
402 | \n", "jRCT2061230009 | \n", "NCT05485766 | \n", "NaN | \n", "gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP... | \n", "トリプルネガティブ乳がん | \n", "トリプルネガティブ乳がん | \n", "Triple Negative Breast Neoplasms | \n", "術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク... | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "1)Male/female subjects who are at least 18 yea... | \n", "1) Subjects who has a positive urine pregnancy... | \n", "18age old exceed | \n", "No limit | \n", "Both | \n", "NaN | \n", "Triple Negative Breast Cancer, Breast Neoplasm... | \n", "Drug: Pembrolizumab 200 mg fixed dose, IV, eve... | \n", "[Triple Negative, Breast Neoplasms] | \n", "
463 | \n", "jRCT2061220087 | \n", "NCT05629585 | \n", "NaN | \n", "術前薬物療法後の外科的切除時に乳房及び/又は腋窩リンパ節に浸潤性残存病変を有するステージI~... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Participant must be >= 18 years at the time of... | \n", "Stage IV (metastatic) TNBC. History of prior i... | \n", "18age old over | \n", "130age old under | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... | \n", "[Breast Cancer] | \n", "
515 | \n", "jRCT2031220276 | \n", "NCT05307705 | \n", "NaN | \n", "PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... | \n", "乳がん | \n", "乳がん | \n", "Breast Cancer | \n", "LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Have advanced breast cancer or another solid ... | \n", "-Medical Conditions -Colorectal cancer -Endome... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... | \n", "[Breast Cancer] | \n", "
590 | \n", "jRCT2031210585 | \n", "NCT05123482 | \n", "NaN | \n", "進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... | \n", "乳癌、胆道癌、卵巣癌、子宮内膜癌 | \n", "乳癌、胆道癌、卵巣癌、子宮内膜癌 | \n", "Breast Cancer, Biliary Tract Carcinoma, Ovaria... | \n", "進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 | \n", "1-2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Age18 years or more - Relapsed/metastatic so... | \n", "- Treatment with any of the following: 1. Nitr... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Sub-study1 AZD8205 Monotherapy AZD8205 is an a... | \n", "[Breast Cancer, Biliary Tract Carcinoma, Ovari... | \n", "
629 | \n", "jRCT2052210099 | \n", "NaN | \n", "NaN | \n", "乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... | \n", "2 | \n", "NaN | \n", "... | \n", "screening | \n", "Breast cancer (including suspected) (1) One of... | \n", "(1) There is trauma with bleeding on the breas... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "The test using IGS-0001 will be performed twic... | \n", "[Breast Cancer] | \n", "
729 | \n", "jRCT2031200057 | \n", "NaN | \n", "NaN | \n", "治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "<Disease Characteristics> 1)Patients with inop... | \n", "1)Patients correspond to either of the followi... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "Breast cancer | \n", "For the target tumor, the dose settled at each... | \n", "[Breast Cancer] | \n", "
14 rows × 40 columns
\n", "\n", " | JRCT ID | \n", "NCT No | \n", "JapicCTI No | \n", "Title | \n", "TargetJ | \n", "Target | \n", "TargetEnglish | \n", "研究・治験の目的 | \n", "試験等のフェーズ | \n", "試験の種類 | \n", "... | \n", "purpose | \n", "Inclusion Criteria | \n", "Exclusion Criteria | \n", "Age Minimum | \n", "Age Maximum | \n", "Gender | \n", "Discontinuation Criteria | \n", "Keyword | \n", "Intervention(s) | \n", "TargetWord | \n", "
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
157 | \n", "jRCT2052240059 | \n", "NaN | \n", "NaN | \n", "遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... | \n", "2 | \n", "NaN | \n", "... | \n", "diagnostic purpose | \n", "1. Histologically confirmed invasive breast ca... | \n", "1. History of other malignancy within the last... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "Omitting breast surgery after preoperative che... | \n", "[Breast cancer] | \n", "
170 | \n", "jRCT2031240096 | \n", "NCT06380751 | \n", "NaN | \n", "本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... | \n", "進行乳癌 | \n", "進行乳癌 | \n", "Advanced Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Adult females, pre/peri-menopausal and/or po... | \n", "- Participants with history of MDS/AML or with... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Experimental: Arm 1: saruparib (AZD5305) plus ... | \n", "[Advanced Breast Cancer] | \n", "
215 | \n", "jRCT2031230723 | \n", "NCT06112379 | \n", "NaN | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "1. Participant must be >= 18 years at the time... | \n", "1. As judged by the investigator, any evidence... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "- Experimental arm: Dato-DXd plus durvalumab n... | \n", "[Breast Cancer] | \n", "
240 | \n", "jRCT2061230102 | \n", "NCT06103864 | \n", "NaN | \n", "Programmed death-ligand(PD-L1)陽性の局所再発手術不能又は転移性... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Histologically or cytologically documented loc... | \n", "As judged by investigator, severe or uncontrol... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... | \n", "[Breast Cancer] | \n", "
307 | \n", "jRCT2061230074 | \n", "NCT05952557 | \n", "NaN | \n", "根治的局所治療(化学療法の併用または非併用)を受けて疾患の兆候のない、再発リスクが中間~高リ... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Women and Men; 18 years or more at the time ... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "NaN | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "
342 | \n", "jRCT2051230094 | \n", "NCT05794906 | \n", "NaN | \n", "前立腺癌の高リスク生化学的再発(BCR)患者を対象としたアンドロゲン遮断療法(ADT)を併用... | \n", "前立腺癌 | \n", "前立腺癌 | \n", "prostate cancer | \n", "BAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Histologically or cytologically confirmed ad... | \n", "- Pathological finding consistent with small c... | \n", "18age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "Drug: Darolutamide (BAY1841788, Nubeqa) Coated... | \n", "[prostate cancer] | \n", "
351 | \n", "jRCT2031230279 | \n", "NCT05862285 | \n", "NaN | \n", "GENENTECH社及び/又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... | \n", "癌 | \n", "癌 | \n", "Cancer | \n", "本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Eligible for continuing Roche IMP-based ther... | \n", "- Meet any of the study treatment discontinuat... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Ipatasertib: Ipatasertib will be administered ... | \n", "[Cancer] | \n", "
388 | \n", "jRCT2031230109 | \n", "NCT05514054 | \n", "NaN | \n", "EMBER-4:2~5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Neoplasms | \n", "早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験 | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Have a diagnosis of ER+, HER2- early-stage, r... | \n", "-Have any evidence of metastatic disease (incl... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: Imlunestrant Administered orally. Other... | \n", "[Breast Neoplasms] | \n", "
392 | \n", "jRCT2031230096 | \n", "NCT05774951 | \n", "NaN | \n", "根治的局所領域療法(化学療法の併用または非併用)および標準補助内分泌療法(ET)を少なくとも... | \n", "乳がん、早期乳がん | \n", "乳がん、早期乳がん | \n", "Breast Cancer, Early Breast Cancer | \n", "Treatment | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Women and Men, greater than or equal to 18 y... | \n", "- Inoperable locally advanced or metastatic br... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "arm A: continue with SoC ET as directed by inv... | \n", "[Breast Cancer, Early Breast Cancer] | \n", "
463 | \n", "jRCT2061220087 | \n", "NCT05629585 | \n", "NaN | \n", "術前薬物療法後の外科的切除時に乳房及び/又は腋窩リンパ節に浸潤性残存病変を有するステージI~... | \n", "乳癌 | \n", "乳癌 | \n", "Breast Cancer | \n", "術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "Participant must be >= 18 years at the time of... | \n", "Stage IV (metastatic) TNBC. History of prior i... | \n", "18age old over | \n", "130age old under | \n", "Both | \n", "NaN | \n", "NaN | \n", "Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... | \n", "[Breast Cancer] | \n", "
515 | \n", "jRCT2031220276 | \n", "NCT05307705 | \n", "NaN | \n", "PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... | \n", "乳がん | \n", "乳がん | \n", "Breast Cancer | \n", "LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "-Have advanced breast cancer or another solid ... | \n", "-Medical Conditions -Colorectal cancer -Endome... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... | \n", "[Breast Cancer] | \n", "
593 | \n", "jRCT2031210560 | \n", "NCT05061823 | \n", "NaN | \n", "複数のBintrafusp alfa(M7824)臨床試験の被験者を対象に長期データを収集す... | \n", "固形癌 | \n", "固形癌 | \n", "Cancer | \n", "本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... | \n", "3 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Participants who are currently enrolled in a... | \n", "- Participants who are pregnant or currently i... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "Participants who are continuing treatment with... | \n", "[Cancer] | \n", "
600 | \n", "jRCT2041210123 | \n", "NCT05114746 | \n", "NaN | \n", "進行性PSMA陽性転移性去勢抵抗性前立腺がん(mCRPC)を有する患者を対象に177Lu-P... | \n", "前立腺癌 | \n", "前立腺癌 | \n", "Prostate Cancer | \n", "本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与... | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- ECOG performance status: 1. Post-taxane popu... | \n", "- Previous treatment with any of the following... | \n", "20age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "Radiation: 177Lu-PSMA-617 administered intrave... | \n", "[Prostate Cancer] | \n", "
629 | \n", "jRCT2052210099 | \n", "NaN | \n", "NaN | \n", "乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... | \n", "2 | \n", "NaN | \n", "... | \n", "screening | \n", "Breast cancer (including suspected) (1) One of... | \n", "(1) There is trauma with bleeding on the breas... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "NaN | \n", "The test using IGS-0001 will be performed twic... | \n", "[Breast cancer] | \n", "
691 | \n", "jRCT2031200384 | \n", "NCT04221542 | \n", "NaN | \n", "転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性... | \n", "前立腺がん | \n", "前立腺がん | \n", "Prostate Cancer | \n", "成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Parts 1, 2, and 5: Participants with histolo... | \n", "- Pathological finding consistent with pure sm... | \n", "18age old over | \n", "No limit | \n", "Male | \n", "NaN | \n", "NaN | \n", "- Experimental: Part 1: AMG 509 Intravenous (I... | \n", "[Prostate Cancer] | \n", "
698 | \n", "jRCT2071200086 | \n", "NCT04640623 | \n", "NaN | \n", "膀胱全摘除術に不適格である,又は膀胱全摘除術を選択しなかった,カルメット・ゲラン桿菌(BCG... | \n", "膀胱癌 | \n", "膀胱癌 | \n", "Bladder Cancer | \n", "試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT... | \n", "2 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "- Histologically confirmed diagnosis of persis... | \n", "- Histologically confirmed, muscle-invasive, l... | \n", "18age old over | \n", "No limit | \n", "Both | \n", "NaN | \n", "NaN | \n", "TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-... | \n", "[Bladder Cancer] | \n", "
729 | \n", "jRCT2031200057 | \n", "NaN | \n", "NaN | \n", "治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 | \n", "乳がん | \n", "乳がん | \n", "Breast cancer | \n", "TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... | \n", "1 | \n", "NaN | \n", "... | \n", "treatment purpose | \n", "<Disease Characteristics> 1)Patients with inop... | \n", "1)Patients correspond to either of the followi... | \n", "20age old over | \n", "No limit | \n", "Female | \n", "NaN | \n", "Breast cancer | \n", "For the target tumor, the dose settled at each... | \n", "[Breast cancer] | \n", "
17 rows × 40 columns
\n", "